Briacell Therapeutics (BCT) Shares Up 13.6%

Briacell Therapeutics Corp (CVE:BCT) shares shot up 13.6% during trading on Wednesday . The company traded as high as C$0.13 and last traded at C$0.13. 682,200 shares were traded during mid-day trading, an increase of 125% from the average session volume of 303,817 shares. The stock had previously closed at C$0.11.

The company has a quick ratio of 0.85, a current ratio of 0.96 and a debt-to-equity ratio of 228.18. The stock has a market capitalization of $17.75 million and a P/E ratio of -2.93.

Briacell Therapeutics (CVE:BCT) last released its earnings results on Friday, December 28th. The company reported C($0.01) earnings per share (EPS) for the quarter.

COPYRIGHT VIOLATION WARNING: This news story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2019/03/15/briacell-therapeutics-bct-shares-up-13-6.html.

Briacell Therapeutics Company Profile (CVE:BCT)

BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, engages in developing personalized treatments for cancer. Its lead product candidate, Bria-IMT, is being tested in a clinical trial in combination with pembrolizumab (KEYTRUDA; manufactured by Merck & Co, Inc) in patients with advanced breast cancer.

Read More: Trading Ex-Dividend

Receive News & Ratings for Briacell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Briacell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.